Kam Zaki

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 123 citations · Full text

Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

R. Wendel Naumann, Ana Oaknin, Tim Meyer et al. · Annals of Oncology · 2019 · 89 citations · Full text

Checkmate 358, Cervical Cancer, Medicine +7

Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity

Joanne Marie M. Del Rosario, Matthew D. Smith, Kam Zaki et al. · Frontiers in Immunology · 2020 · 30 citations · Full text

Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study

Liz Jamieson, Martin Förster, Kam Zaki et al. · BMC Cancer · 2020 · 28 citations · Full text

Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer

James Spicer, Bristi Basu, Ana Montes et al. · Cancer Research · 2020 · 18 citations

Ige Antibodies, Immunology, Immunoediting +22